Circulating SIRT6 Expression, Effect on Aging Quality (Sirt6)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT01567176
First received: March 8, 2012
Last updated: January 17, 2013
Last verified: February 2012
  Purpose

This study follows the results of the COMPALICLAMP study (NCT00951392) where the investigators showed a differential expression of sirtuins protein isoforms, Sirt6, in muscle depending on the quality of aging. The investigators seek to confirm this difference in expression level of circulating leukocytes on a larger sample.


Condition Intervention
Aging
Biological: Blood sample

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Circulating Expression Measurement of a Sirtuin Protein Isoform, Sirt6, as an Early Marker of Aging Quality

Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:
  • Sirt6 expression in circulating leukocytes based on the aging quality [ Time Frame: participants will be followed for the duration of the visit, an expected average of 1 day ] [ Designated as safety issue: No ]
    analysis by quantitative RT-PCR method


Secondary Outcome Measures:
  • hand and forearm muscular strength measurement [ Time Frame: participants will be followed for the duration of the visit, an expected average of 1 day ] [ Designated as safety issue: No ]
    Hand Grip strength test

  • Physical examination and anthropometric measurement [ Time Frame: participants will be followed for the duration of the visit, an expected average of 1 day ] [ Designated as safety issue: No ]
    Measurement of the weight, height, waist, hips, blood pressure, pulse.

  • Cognitive assessment [ Time Frame: participants will be followed for the duration of the visit, an expected average of 1 day ] [ Designated as safety issue: No ]
    MMSE (Mini Mental State Examination), Five-word test, clock drawing

  • Physical Activity questionnaire [ Time Frame: participants will be followed for the duration of the visit, an expected average of 1 day ] [ Designated as safety issue: No ]
    MAQ (Modifiable Activity Questionnaire)


Enrollment: 60
Study Start Date: March 2012
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Single Arm Biological: Blood sample
It is a single cross sectional study. All outcome measures will be taken during the investigation with physical examination, questionnaire and a blood sample

  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Volunteers from the SUVIMAX 2 aging cohort
  • Men and women
  • Older than 60
  • Subject with a global aging quality score of 1 or 3 in the SU.VI.MAX. 2 study
  • Covered by Health Insurance System

Exclusion Criteria:

  • Subject not in compliance with the recommendation of French National Law
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01567176

Locations
France
Centre de recherche en nutrition humaine Rhone-Alpes
Pierre Bénite, France, 69310
Centre de Recherche en Nutrition Humaine
Pierre Bénite, France, 69310
Sponsors and Collaborators
Hospices Civils de Lyon
Investigators
Principal Investigator: Martine LAVILLE, Pr Centre de recherche en nutrition humaine Rhone-Alpes
  More Information

No publications provided

Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT01567176     History of Changes
Other Study ID Numbers: 2011.674
Study First Received: March 8, 2012
Last Updated: January 17, 2013
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Hospices Civils de Lyon:
Sirtuins
Aging
Metabolic disease

ClinicalTrials.gov processed this record on April 16, 2014